Previous 10 | Next 10 |
Carl Icahn controlled ENZN to date has been a multi-year, slow motion liquidation story. Enzon has been regularly paying out royalty and milestone revenue as dividends since the company shrunk to a shell back in 2013/2014. The company recently paid a 12 cent dividend, having closed at 25.7 c...
The following slide deck was published by Sesen Bio, Inc. in conjunction with this Read more ...
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the H.C. Wainwright 21 st Annual Global Investment Conference on Tuesday, Septem...
Company Appoints Monica Forbes as Chief Financial Officer and Kirstin Anderson as Principal Accounting Officer Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the ap...
On Aug. 8, Sesen Bio ( SESN ), reported Q2 earnings and updates from the Phase 3 VISTA trial for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC). Following the VISTA trial update, the stock price rose by more than 5% in after-hours trading, but the subsequent trading day yanked it back ...
Sesen Bio (NASDAQ: SESN ) is up 5.1% after hours after reporting positive early data from its Phase 3 VISTA trial of Vicinium for treatment of high-risk non-muscle invasive bladder cancer. More news on: Sesen Bio, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Updated 12-month Phase 3 Data will Serve as the Basis for Submission of the BLA On Track for Anticipated Initiation of BLA Submission in 4Q 2019 Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of p...
Sesen Bio (NASDAQ: SESN ) expands its leadership team with the appointment of industry leaders to several key roles: More news on: Sesen Bio, Inc., Healthcare stocks news, Read more ...
Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the Canaccord Genuity 39th Annual Growth Conference on Wednesday, August 7, 201...
Today, we want to share our analysis of Sesen Bio (SESN) with you. The company's stock price has declined by more than 35% since mid-June after the release of secondary offering news. However, the company has a debt-free balance sheet with ~50% of its market cap in cash, and its lead drug has ...
News, Short Squeeze, Breakout and More Instantly...
Sesen Bio Inc. Company Name:
SESN Stock Symbol:
NASDAQ Market:
Declares Special Dividend in the Aggregate of $75 Million Approximately 88% Voted in Favor of the Merger at the Special Meeting Merger on Track to Close on March 7, 2023 Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today anno...
Sesen Bio Board Believes the Pending Merger with Carisma is the Most Value-Maximizing Option for Stockholders Reiterates Support from Several of Sesen Bio’s Largest Stockholders and Two Leading Independent Proxy Advisors Sesen Bio Board Unanimously Recommends All St...
Positive Recommendations Underscore that Carisma Merger Maximizes Value for Sesen Bio Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Follow ISS and Glass Lewis’s Recommendations to Vote “FOR” Value Maximizing Merger on WHITE ...